Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: A randomized Phase 2 clinical trial.

de Bruyn G, Saleh J, Workman D, Pollak R, Elinoff V, Fraser NJ, Lefebvre G, Martens M, Mills RE, Nathan R, Trevino M, van Cleeff M, Foglia G, Ozol-Godfrey A, Patel DM, Pietrobon PJ, Gesser R; H-030-012 Clinical Investigator Study Team.

Vaccine. 2016 Apr 27;34(19):2170-8. doi: 10.1016/j.vaccine.2016.03.028. Epub 2016 Mar 21.

2.

A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.

Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, Restrepo JA, Stuart G, Woelber L, Yang YC, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Chan IS, Chen J, Gesser R, Moeller E, Ritter M, Vuocolo S, Luxembourg A; Broad Spectrum HPV Vaccine Study.

N Engl J Med. 2015 Feb 19;372(8):711-23. doi: 10.1056/NEJMoa1405044.

3.

A seamless phase IIB/III adaptive outcome trial: design rationale and implementation challenges.

Chen YH, Gesser R, Luxembourg A.

Clin Trials. 2015 Feb;12(1):84-90. doi: 10.1177/1740774514552110. Epub 2014 Oct 1.

PMID:
25278227
4.

Validation of the Simple Shoulder Test in a Portuguese-Brazilian population. Is the latent variable structure and validation of the Simple Shoulder Test Stable across cultures?

Neto JO, Gesser RL, Steglich V, Bonilauri Ferreira AP, Gandhi M, Vissoci JR, Pietrobon R.

PLoS One. 2013 May 13;8(5):e62890. doi: 10.1371/journal.pone.0062890. Print 2013.

5.

Multiplexed serologic assay for nine anogenital human papillomavirus types.

Opalka D, Matys K, Bojczuk P, Green T, Gesser R, Saah A, Haupt R, Dutko F, Esser MT.

Clin Vaccine Immunol. 2010 May;17(5):818-27. doi: 10.1128/CVI.00348-09. Epub 2010 Mar 17.

6.

Multidisciplinary evaluation and management of dysphagia: the role for otolaryngologists.

Duval M, Black MA, Gesser R, Krug M, Ayotte D.

J Otolaryngol Head Neck Surg. 2009 Apr;38(2):227-32.

PMID:
19442373
7.

Safety and tolerability of ertapenem versus ceftriaxone in a double-blind study performed in children with complicated urinary tract infection, community-acquired pneumonia or skin and soft-tissue infection.

Arguedas A, Cespedes J, Botet FA, Blumer J, Yogev R, Gesser R, Wang J, West J, Snyder T, Wimmer W; Protocol 036 Study Group.

Int J Antimicrob Agents. 2009 Feb;33(2):163-7. doi: 10.1016/j.ijantimicag.2008.08.005. Epub 2008 Oct 21.

PMID:
18945594
8.

Ertapenem or ticarcillin/clavulanate for the treatment of intra-abdominal infections or acute pelvic infections in pediatric patients.

Yellin AE, Johnson J, Higareda I, Congeni BL, Arrieta AC, Fernsler D, West J, Gesser R.

Am J Surg. 2007 Sep;194(3):367-74.

PMID:
17693284
9.

Radiotherapy versus surgery for early T1-T2 glottic carcinoma.

Mlynarek A, Kost K, Gesser R.

J Otolaryngol. 2006 Dec;35(6):413-9.

PMID:
17380837
11.

Safety and tolerability of ertapenem.

Teppler H, Gesser RM, Friedland IR, Woods GL, Meibohm A, Herman G, Mistry G, Isaacs R.

J Antimicrob Chemother. 2004 Jun;53 Suppl 2:ii75-81. Review.

PMID:
15150186
13.

Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam.

Solomkin J, Teppler H, Graham DR, Gesser RM, Meibohm AR, Roy S, Woods GL.

J Antimicrob Chemother. 2004 Jun;53 Suppl 2:ii51-7.

PMID:
15150183
15.

Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data.

Gesser RM, McCarroll K, Teppler H, Woods GL.

J Antimicrob Chemother. 2003 May;51(5):1253-60. Epub 2003 Apr 14.

PMID:
12697633
16.

Surgical infections with enterococcus: outcome in patients treated with ertapenem versus piperacillin-tazobactam.

Teppler H, McCarroll K, Gesser RM, Woods GL.

Surg Infect (Larchmt). 2002 Winter;3(4):337-49.

PMID:
12697080
17.
18.

Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study.

Tomera KM, Burdmann EA, Reyna OG, Jiang Q, Wimmer WM, Woods GL, Gesser RM; Protocol 014 Study Group.

Antimicrob Agents Chemother. 2002 Sep;46(9):2895-900.

19.
20.

A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults.

Jimenez-Cruz F, Jasovich A, Cajigas J, Jiang Q, Imbeault D, Woods GL, Gesser RM; Protocol 021 Study Group.

Urology. 2002 Jul;60(1):16-22.

PMID:
12100914

Supplemental Content

Loading ...
Support Center